Trevi Therapeutics (NASDAQ:TRVI) Rating Reiterated by Needham & Company LLC

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 target price on the stock. Needham & Company LLC’s target price suggests a potential upside of 200.75% from the company’s previous close.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price objective on shares of Trevi Therapeutics in a report on Thursday, March 21st.

Trevi Therapeutics Stock Performance

Shares of TRVI traded down $0.24 during trading hours on Wednesday, hitting $2.66. 22,398 shares of the company were exchanged, compared to its average volume of 257,480. The company has a market cap of $187.34 million, a PE ratio of -9.17 and a beta of 0.91. The firm’s 50 day moving average is $3.04 and its 200-day moving average is $2.06. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Wednesday, March 20th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.02. As a group, equities analysts forecast that Trevi Therapeutics will post -0.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TRVI. Frazier Life Sciences Management L.P. raised its position in shares of Trevi Therapeutics by 7.3% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock worth $9,891,000 after acquiring an additional 500,000 shares during the last quarter. Opaleye Management Inc. raised its position in shares of Trevi Therapeutics by 48.6% during the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after acquiring an additional 829,100 shares during the last quarter. Silverarc Capital Management LLC grew its stake in shares of Trevi Therapeutics by 4.7% during the third quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock worth $2,022,000 after purchasing an additional 41,491 shares during the period. SG Americas Securities LLC grew its stake in shares of Trevi Therapeutics by 401.4% during the fourth quarter. SG Americas Securities LLC now owns 98,253 shares of the company’s stock worth $132,000 after purchasing an additional 78,656 shares during the period. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Trevi Therapeutics during the first quarter worth $208,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.